105<del>65064</del> - GAU: 3771 Approved for use through

Inder the Pap	erwork Reduction Act	t of 199	5, no persons are required to		tion unless it contains a valid OMB control numb		
Substitu	te for form 1449A/PT	0		Complete if Known			
	r the Paperwork Reduction Act of 1995, no persons are required Substitute for form 1449APTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)  Sheet 1 of 2		Application Number	10/565,064			
INF		SCLOSURE	Filing Date	06/25/2004			
STA		PPLICANT	First Named Inventor	Houzego, Peter, John, et al.			
			Art Unit	TBA			
	(Use as many sh	eets a	s necessary)	Examiner Name	TBA		
Sheet	1	of	2	Attorney Docket Number	PC3749A		

			U.S. PAT	TENT DOCUMENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials'	No.1	Number-Kind Code 2 (* hour)	MM-DD-YYYY	Applicant of Cited Document		
		US- 4,811,731A	03-14-1989	Rand Paul K et al		
		US- 5,657,749A	08-19-1997	Cox Peter Erich		
		US- 5,301,666 A	04-12-1994	Lerk Coenraad et al		
		US- 6,182,655 B1	02-06-2001	Eggimann Thomas et al		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		us.				

			FOR	EIGN PATENT DOC	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Docu Country Code <sup>3</sup> Number <sup>4</sup>	Kind Code 5	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T®
		WO 01/85097 A	(if known)	11-15-2001	Innovative Devicess LLC	Figures Appear	H
		EP 1,106,196 A		06-13-2001	Atsugi Unisia Corp		П
		WO 02/094357 A		11-28-2002	Asking Lars		
		WO 01/17595 A		03-15-2001	Innovata Biomed Ltd.		
		DE 33 48 370 C		10-11-2001	Glaxo Group Ltd.		
		WO 03/015857 A		02-27-2003	Jennings Douglas Ivan		
		EP 0 469 814 A		02-05-1992	Lilly Industries Ltd.		П
		WO 96/33759 A		10-31-1996	Dura Pharma Inc.		
		WO 03/024514 A		03-27-2003	Advent Pharmaceuticals PTY		П
		WO 02/24263 A		03-28-2002	Pike Gregory Charles		

	110 022 1202 14	OD HO HOOL TIME	Gregory Charte	•	
Examiner Signature	/Valerie Skorupa/		Date Considered	11/28/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese paient documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document.

\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

\*Applicant is to place a check mark

here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

Sheet 2

PTO/SB/08A (07-05)

Substitute for form 1449/PTO	Complete if Known
Under the Paperwork Reduction Act of 1995, no persons are required to re	spond to a collection of information unless it contains a valid OMB control number
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC
	Approved for use through 07/31/2006, OMB 0651-003

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 2

Application Number 10/565.064 Filing Date 06/25/2004 First Named Inventor Houzego, Peter, John, et al. Art Unit TBA Evaminer Name TBA Attorney Docket Number PC3749A

			U. S. PATENT D		
Examiner nitials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code <sup>2 (F known)</sup>			Figures Appear
		US-			
		US-			
	$\vdash$	US-			
		US-			
	<del>                                     </del>	US-	<b> </b>		
	-	US-			
		US-			
	-	US-			
	-	US-			
		US-			
		US-	1		
		US-	1		
	┢	US-			-
	$\vdash$	US-			+
		US-			<del> </del>
	_	US-			
	$\vdash$	US-			
	$\vdash$	US-	+	<del></del>	
	_	US-	+ +		

		FOREIG	ON PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> " Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		WO 95/11715 A	05-04-1995	Tenax Corp		
		GB 2 242 134 A	09-25-1991	Glaxo Group Ltd.		
	-		+			Н
	-					⊢
					J.,	

Date Considered 11/28/2009 /Valerie Skorupa/ Signature

"EXAMINER: Initial if milerence considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicants unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.uspect.goog over VMEPP 901.00.4. "Enter Office that issued the document, by the two-deter code (WMPD Standard ST.3)." For Japanese patient document, in the inclusion of the year of the reign of the Emperor must precode the serial number of the patient document. "Kind of document with the prographies" public as included not not document and WMPD Standard ST.1 if a possible. "Applicant is to place a check mark here if English language Translation is attached

Translation is attached.
This collection of importance is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and solutions; the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete its form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patert and Trademan Office, P.O. 80: 1459, Alexandris, V.A. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.